- ASSISTANT PROFESSOR | Medicine, Gastroenterology
- Hospital Affiliations
- Mount Sinai St. Luke's and Mount Sinai West
- The Mount Sinai Hospital
Ari Grinspan, MD, is an Assistant Professor in the Department of Medicine, Division of Gastroenterology and the Director of the GI Microbial Therapeutics. He received his medical degree from the Albert Einstein College of Medicine in New York and completed his Internal Medicine training at New York-Presbyterian Hospital. He completed his fellowship in Gastroenterology at Mount Sinai Medical Center, where he remains as full-time faculty.
Dr. Grinspan pioneered the Fecal Microbiota Transplant (FMT) program to treat recurrent and refractory Clostridium difficile infection at Mount Sinai, which has developed into a referral center for the tri-state area. His research focuses on exploring the mechanism and clinical utility of FMT in Clostridium difficile infection and Inflammatory Bowel Disease.
For more information on FMT, please read Dr. Grinspan's articles: Guest commentary: The exciting future of fecal microbiota transplant and Fecal Microbiota Transplantation for Inflammatory Bowel Disease,
American Board of Internal Medicine
- Antibiotic-Associated Colitis-C Difficile
- Colon Polypectomy
- Colon Polyps
- Colorectal Cancer
- Crohn's Disease
- Fecal Microbiota Transplant (FMT)
- Flexible Sigmoidoscopy
- Inflammatory Bowel Disease
- Iron-Deficiency Anemia
- Peptic Ulcer
- Ulcerative Colitis
- Upper GI Endoscopy
MD, Albert Einstein College of Medicine
Residency, Internal Medicine
New York Presbyterian - Weill Cornell Medical Center
Mount Sinai Hospital
Chief GI Fellow
Mount Sinai Medical Center
Daniel M. Libby MD Program Directors Award
New York-Presbyterian Hospital
Assistant Chief Resident
New York-Presbyterian Hospital
Alpha Omega Alpha
Albert Einstein College of Medicine
Phi Beta Kappa
University of Pennsylvania
Fecal Microbiota Transplantation (FMT)
Dr. Grinspan has pioneered the Fecal Microbiota Transplantation (FMT) program at Mount Sinai to treat recurrent and refractory Clostridium difficile infection.
An Open-Label Extension of Study SERES-004 Evaluating SER-109 in Patients with Recurrent Clostridium difficile Infection
The purpose of this study is to see how safe and effective SER-109 in keeping CDI from coming back. This study is an extension study to the SERES-004 study. Subjects may qualify to take part in this research study because they are currently participating in the SERES-004...
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr. Grinspan has not yet completed reporting of Industry relationships.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.